Woman Who Left Fortune 500 Career to Care for Mother with Alzheimer's Faces Financial Hardship
Kathy Mullen quit her job at Nike to become a full-time caregiver for her mother with Alzheimer's disease, a decision that left her financially and physically devastated. Mullen spent down her retirement savings and her mother's Social Security on medical care and living expenses over six years. Her story highlights the financial vulnerability of family caregivers in the United States who lack adequate long-term care support systems.
Kathy Mullen, 64, left a successful decade-long career at Nike in Portland, Oregon to move to North Texas in 2010 to care for her mother, who had been diagnosed with early-onset dementia in 2007. Unable to afford professional long-term care facilities and facing family expectations as the oldest child and only daughter, Mullen became her mother's primary caregiver for six years until her mother's death in February 2016. She liquidated her retirement savings and relied on her mother's Social Security, but these resources were quickly depleted by medical visits, medications, and daily care expenses. Though she received some support from the Alzheimer's Association and an adult day care program, Mullen's own health deteriorated from the physical and emotional demands of caregiving. Her experience underscores the broader challenge facing American families who must choose between employment and caregiving, often resulting in financial ruin and health consequences.
What different sources said
- Business InsiderLeft
I gave up my career at a Fortune 500 company to care for my mom full-time. Now, I struggle to pay my bills.
Related

Multi-Cancer Blood Test Galleri Fails Primary Trial Endpoint
A major clinical trial of Galleri, a blood test designed to detect multiple cancers early, failed to meet its primary goal of reducing late-stage cancer diagnoses when results were announced in February. Multi-cancer early detection (MCED) tests aim to improve survival rates by identifying disease at earlier, more treatable stages. The failure raises questions about the effectiveness of this promising diagnostic approach despite initial scientific enthusiasm.
Study Uses CPAP Data to Measure Social Jet Lag in Sleep Apnea Patients
Researchers analyzed CPAP adherence records from nearly 3,000 obstructive sleep apnea patients to measure social jet lag—the circadian misalignment between work and free days. About 16-21% of patients showed moderate to severe social jet lag, with prevalence highest in younger and middle-aged adults and declining after age 65. The findings suggest CPAP devices could routinely screen for circadian misalignment, potentially identifying patients who need additional behavioral or activity-based interventions.

FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.